Adaia Albasanz‐Puig

Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance

Gemma Martínez‐Nadal, Pedro Puerta‐Alcalde, Carlota Gudiol et al. · Clinical Infectious Diseases · 2019 · 164 citations

Pharmacy, Infectious Diseases, Microbiology +16

Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa

Carlota Gudiol, Adaia Albasanz‐Puig, Júlia Laporte-Amargós et al. · Antimicrobial Agents and Chemotherapy · 2020 · 58 citations · Full text

Life Sciences, Infectious Diseases, Antimicrobial Pharmacotherapy +16

Oncostatin M is expressed in atherosclerotic lesions: A role for Oncostatin M in the pathogenesis of atherosclerosis

Adaia Albasanz‐Puig, Jacqueline Murray, Michael R. Preusch et al. · Atherosclerosis · 2011 · 49 citations

Medicine, Cardiology, Pathology +12

Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study)

Adaia Albasanz‐Puig, Carlota Gudiol, Pedro Puerta‐Alcalde et al. · Antimicrobial Agents and Chemotherapy · 2021 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy

Ester Márquez‐Algaba, Gloria Iacoboni, Berta Pernas et al. · Transplantation and Cellular Therapy · 2022 · 44 citations · Full text

Medicine, Hematology, Immunology +13